SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-052917
Filing Date
2024-06-14
Accepted
2024-06-14 16:30:24
Documents
3
Period of Report
2024-06-14

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0207659-6k_enlivex.htm 6-K 11201
2 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR ENLIVEX AS OF MARCH 31 ea020765901ex99-1_enlivex.htm EX-99.1 237017
3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF AND FOR THE THREE MONTH PERIO ea020765901ex99-2_enlivex.htm EX-99.2 73769
  Complete submission text file 0001213900-24-052917.txt   323277
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 241045329
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)